Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

6.97EUR
11:35am EDT
Price Change (% chg)

€0.06 (+0.87%)
Prev Close
€6.91
Open
€6.95
Day's High
€6.97
Day's Low
€6.84
Volume
68,996
Avg. Vol
106,957
52-wk High
€8.10
52-wk Low
€2.78

ABLX.BR

Chart for ABLX.BR

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the discovery and development of Nanobodies, a class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and Alzheimer’s disease. The Company’s... (more)

Overall

Beta: 0.80
Market Cap (Mil.): €337.22
Shares Outstanding (Mil.): 48.80
Dividend: --
Yield (%): --

Financials

  ABLX.BR Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -0.65 -- --
ROI: -61.29 -2.58 18.76
ROE: -63.10 -2.66 19.59
Search Stocks

BRIEF-Ablynx Q1 net loss EUR 6.7 million

BRUSSELS, May 15 - Ablynx NV : * Q1 net loss EUR 6.7 million * Net cash at end Q1 82.2 million EUR

15 May 2013

BRIEF-Ablynx shares suspended pending fundraising result

BRUSSELS, Feb 28 - Ablynx NV : * Shares suspended pending results of fundraising - stock market regulator

28 Feb 2013

BRIEF-Ablynx CEO sees partnering deals this year

BRUSSELS, Feb 27 - Ablynx NV : * CEO says during the coming year, expects important new partnering deals * Says net cash burn well controlled at just EUR21.1 million in 2012 * Says EUR62.8 million in cash at end of 2012

27 Feb 2013

BRIEF-Ablynx enters into cancer deal with UK's Spirogen

BRUSSELS, Feb 25 - Ablynx NV : * Ablynx and Spirogen enter into a research collaboration to evaluate the

25 Feb 2013

Ablynx books success with arthritis drug study

BRUSSELS - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.

13 Feb 2013

Ablynx books success with arthritis drug study

BRUSSELS, Feb 13 - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.

13 Feb 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks